1) No cancer cells were detected at any time in the vena cava and aortic blood after the inoculation of nitrogen mustard. However when the mustard was administered in animals treated with fibrinolysin or with heparin cancer cells riappeared in the circulating blood; 2) the number of takes by subcute inoculation of blood of animals inoculated with cancer cells was also reduced with the administration of HN2, heparin or fibrinolysin; 3) following the administration of 100,000 Walker 256 cancer cells pulmonary metastases occurred in 84% of the control groups, in 41% of the nitromin treated group and in 33% of the nitrogen mustard treated group. However when the mustard was administered in animals treated with heparin or fibrinolysin metastases were reduced to 22% and 20% respectively.
Get full access to this article
View all access options for this article.
References
1.
AgostinoD., e ClifftonE. E.: Il fattore coagulazione nella produzione di metastasi: efficacia della fibrinolisina e dell'eparina.Osp. It. Chir., 9: 393–406, 1964.
2.
AgostinoD.: Effetto del trattamento combinato radioterapia ed anticoagulanti sulla produzione di metastasi polmonari in campo sperimentale.Nuntius Radiol., 29, 689–701, 1963.
3.
AgostinoD., GrossiC. E., and ClifftonE. E.: Effect of heparin on circulating Walker carcinosarcoma 256 cells.J. Nat. Cancer Inst., 27: 17–24, 1961.
4.
AshworthT. R.: A case of cancer in which cells similar to those in the tumors were seen in the blood after death.Australian Med. J., 14: 146–147, 1869.
5.
ClifftonE. E., and GrossiC. E.: Effect of human plasmin on the toxic effects and growth of blood-borne metastases of the Brown-Pearce carcinoma and the V2 carcinoma of the rabbit.Cancer, 9: 1147–1152, 1956.
6.
ColeW. H., McDonaldG. O., and RobertsS. S.: Dissemination of cancer and its prevention.J. Roy. Coll. Surg., 4: 218–235, 1959.
7.
De GaetaniG. F., MaioliM., e SavanuzziG.: Inoculazione endovenosa di cellule neoplastiche ed alterazioni polmonari.Neoplasie, 4: 145–178, 1949.
8.
EngellH. C.: Cancer cells in circulating blood: clinical study of occurrence of cancer in peripheral blood and in venous blood draining tumor area at operation.Acta Chir. Scand., Suppl., 201: 1–70, 1955.
9.
EngellH. C.: Cancer cells in the blood. Five to nine years follow-up study.Ann. Surg., 149: 457–461, 1959.
10.
FisherB., and FisherE. R.: Experimental studies of factors which influence hepatic metastases. VIII. Effect of anticoagulants.Surgery, 50: 240–247, 1961.
11.
GrossiC. E., AgostinoD., and ClifftonE. E.: The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinosarcoma.Cancer Res., 20: 605–608, 1960.
12.
GrossiC. E., AgostinoD., MelamedM., and ClifftonE. E.: The effect of human fibrinolysin on survival of carcinosarcoma 256 Walker cells in the blood.Cancer, 14: 957–962, 1961.
13.
HeilbrunnL. V., and WilsonW. L.: The effect of heparin on cell division.Proc. Soc. Exp. Biol. & Med., 70: 179–182, 1949.
14.
JollesB., and GreeningS. G.: Effect of heparin upon tumor growth. Acta Unio Intern.Contra Cancrum, 16: 682–685, 1960.
15.
KreislerR.: Effect of heparin on the growth of a transplantable lymphosarcoma in mice.Science, 115: 145–146, 1952.
16.
LawrenceE. A., BowmanD. E., MooreD. B., and BernsteinG. I.: A throm-boplastic propriety of neoplasms.Surg. Forum, 3: 694–698, 1953.
17.
LippmanM.: The growth-inhibitory action of heparin on the Ehrlich ascites tumor in mice.Cancer Res., 17: 11–14, 1957.
18.
PoolE. H., and DunlopG. R.: Cancer cells in blood stream.Am. J. Cancer, 21: 99–102, 1934.
19.
RobertsS.S., JonassonO., LongL. R., McGrewE. A., and ColeW. H.: Clinical significance of cancer cells in the circulating blood. Two to five years survival.Ann. Surg., 154: 362–371, 1961.
20.
SandbergA. A., and MooreG. E.: Examination of blood for tumor cells.J. Nat. Cancer Inst., 19: 1–12, 1957.
21.
SchleipK.: Zur diagnose von knochenmarkstumorem aus dem blutbefunde.Ztschr. Klin. Med., 59: 261–282, 1906.
22.
SealS. H.: Silicone flotation: a simple quantitative method for the isolation of free floating cancer cells from the blood.Cancer, 12: 590–595, 1959.
23.
StallB. A.: Advanced cancer treated with nitromin. M.J.Australia, 2: 882–887, 1956.
24.
StormO., AmrisC. J., LarsenV., and MogersenB.: Report on the treatment of cancer patients with fibrinolytic enzyme (Lysofibrin Novo).Novo Tera-peutisk Laboratorium A/S Report, March 28, 1963, Copenhagen.
25.
TerranovaT., e ChissoneF.: Il fattore della coagulazione nell'atteccliimento delle cellule neoplastiche nel circolo.Boll. Soc. It. Biol. Sper., 28: 1224–1225, 1952.
26.
VergaV., e AgostinoD.: La crescita e trapiantabilità del carcinoma di Walker 256 in cavità peritoneale di ratti C.River. Riv. Anat. Patol. Oncol., 11: 877–885, 1957.
27.
WardG. R.: The blood in cancer with bone metastases.Lancet, 1: 676–677, 1913.
28.
WatneA. L., RobertsS. S., Mc GrewE. A., and ColeW. H.: The occurrence of cancer cells in the circulating blood and their response to surgery and chemotherapy.Acta Unio Intern. Contra Cancrum, 16: 790–799, 1960.
29.
WatneA. L., SandbergA. A., and MooreG. E.: Prognostic implications of tumor cells in the blood.Proc. Am. Ass. Cancer Res., 3: 160, 1960.
30.
WoodJ. S., HolyokeE. D., and YardleyJ. H.: An experimental study of the influence of adrenal steroids, growth hormone, and anticoagulants on pulmonary metastasis formation in mice.Proc. Am. Ass. Cancer Res., 2: 157–158, 1956.
31.
WoodJ. S.: Mechanism of metastasis production by blood-borne cancer cells.Proc. Cancer Canad. Conf., 4: 167–223, 1961.
